2007-2022 年前列腺癌检测中活检前 MRI 使用趋势。
Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022.
发表日期:2024 Sep 21
作者:
Simon John Christoph Soerensen, Shufeng Li, Marvin E Langston, Richard E Fan, Mirabela Rusu, Geoffrey A Sonn
来源:
PROSTATE CANCER AND PROSTATIC DISEASES
摘要:
由于已证实的好处,临床指南倾向于在前列腺活检之前进行 MRI。然而,美国各地的采用模式尚不清楚。本研究使用 Merative™ Marketscan® Commercial
Clinical guidelines favor MRI before prostate biopsy due to proven benefits. However, adoption patterns across the US are unclear.This study used the Merative™ Marketscan® Commercial & Medicare Databases to analyze 872,829 prostate biopsies in 726,663 men from 2007-2022. Pre-biopsy pelvic MRI within 90 days was the primary outcome. Descriptive statistics and generalized estimating equations assessed changes over time, urban-rural differences, and state-level variation.Pre-biopsy MRI utilization increased significantly from 0.5% in 2007 to 35.5% in 2022, with faster adoption in urban areas (36.1% in 2022) versus rural areas (28.3% in 2022). Geographic disparities were notable, with higher utilization in California, New York, and Minnesota, and lower rates in the Southeast and Mountain West.The study reveals a paradigm shift in prostate cancer diagnostics towards MRI-guided approaches, influenced by evolving guidelines and clinical evidence. Disparities in access, particularly in rural areas and specific regions, highlight the need for targeted interventions to ensure equitable access to advanced diagnostic techniques.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.